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Objective: Interest has grown regarding photobiomodulation (PBM) with low-level light 
therapy, which has been shown to positively affect the stages of the wound healing process. In a 
real-life context clinical setting, the objective of the EUREKA study was to investigate efficacy, 
safety, and quality of life associated with the use of a BioPhotonic gel (LumiHeal™) in the 
treatment of chronic wounds such as venous leg ulcers (VLUs), diabetic foot ulcers (DFUs), and 
pressure ulcers (PUs). This BioPhotonic gel represents a new, first-in-class emission spectrum 
of light, including fluorescence, to induce PBM and modulate healing.
Design: The multicenter, prospective, interventional, uncontrolled, open-label study enrolled 
100 patients in 12 wound centers in Italy. We performed an early interim analysis based on the 
first 33 subjects (13 VLU, 17 DFU, 3 PU) in seven centers who completed the study.
Main results: Seventeen patients (52%) achieved total wound closure (full re-epithelialization 
for 2 weeks) during the study period. Two patients (6%) were considered “almost closed” 
(decrease of the wound area of more than 90% at study end) and three others (9%) were con-
sidered “ready for skin grafting”. No related serious adverse events were observed, and the 
compliance was excellent. After the treatment, the average time to “pain-free” was 11.9 days in 
the VLU group. Quality of life was improved with overall increase of 26.4% of the total score 
(Cardiff Wound Impact Schedule, p=0.001).
Conclusion: The study revealed a positive efficacy profile of the BioPhotonic gel in promoting 
wound healing and reactivating the healing process in different types of chronic, hard-to-heal 
wounds. The treatment was shown to be safe and well tolerated by the patients, and a reduc-
tion of pain perception was also detected during the treatment period. The improvement of the 
quality of life was accompanied by a high level of clinician satisfaction.
Keywords: photobiomodulation, fluorescence biomodulation, biophotonics, phototherapy, light, 
venous leg ulcers, VLUs, pressure ulcers, PUs, diabetic foot ulcers, DFUs, hard-to-heal wounds
Introduction
Chronic wounds such as pressure ulcers (PUs), venous leg ulcers (VLUs), and diabetic 
foot ulcers (DFUs) remain a challenging clinical problem and efficient wound manage-
ment is crucial to effectively assist the healing process.1,2 The socioeconomic burden 
of chronic wounds represents an enormous annual cost for health care systems. The 
impact of chronic wounds and their high rate of occurrence is also worsened by the 
aging global population.3,4 For example, it has been estimated that chronic wounds 
have an incidence rate of 120 per 100,000 people aged between 45 and 65 years and 
it rises to 800 per 100,000 people .75 years of age.4–6 In addition, it is important to 
highlight that underlying pathologies, particularly diabetes, may explain the failure of 
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healing of these chronic wounds.7 The prevalence of DFUs 
ranges from 4% to 10% among patients with diabetes, and 
the lifetime incidence is reported to be as high as 25%.8,9 
Moreover, in the case of VLUs, it has been reported that they 
recur in 70% of cases, and recent data demonstrate high VLU 
recurrence rates, ranging from 0% at 6 months to 56% at 
54 months.10,11 Therefore, new treatment options for chronic 
skin ulcers are needed. In this context, the use of low energy 
level light therapy that relies on the effect of photobiomodu-
lation (PBM) is an attractive alternative therapy to enhance 
wound healing and a promising strategy for the management 
of complex chronic wounds.12,13 There has been an increasing 
amount of biomedical research to substantiate physiological 
responses to visible light. The first consideration involves the 
assumption that for low power visible light to have an effect 
on a living biological system such as the skin, the photons 
must be absorbed by electronic absorption bands belonging to 
some molecular chromophore or photoacceptor.14 The second 
important consideration involves the use of the definition 
of PBM as the most suitable term to describe the molecular 
process and resulting beneficial photobiological responses 
involved in non-thermal low-dose light therapies.15
The fluorescence technology of the BioPhotonic gel 
is based on the unique ability of special light-capturing 
molecules (chromophores) to convert light emissions from 
a multi-light emitting diode (LED) lamp into a different 
photons emission spectrum with broader and longer range 
of wavelengths with lower energy (fluorescence). As a result 
of this technology, when skin is exposed to fluorescence it 
induces modulation of biological processes (PBM).16
The beneficial effects of PBM on wound healing might 
be attributed to anti-inflammatory signaling, cell prolifera-
tion, protein synthesis, and decreased bacterial infection.17 
In this exploratory clinical study named EUREKA, we have 
used an interim analysis to investigate efficacy and safety of 
a BioPhotonic gel, known as LumiHeal™ (KLOX Technolo-
gies Inc., Laval, QC, Canada). The BioPhotonic gel consists 
of a gel containing light-absorbing molecules (chromophores) 
that are illuminated by a multi-LED lamp. We evaluated the 
effects of BioPhotonic gel in the treatment of chronic, hard-
to-heal wounds such as PUs, DFUs, and VLUs.
Materials and methods
The Clinical trial identifier at Clinicaltrials.gov is 
NCT03021811.
One hundred subjects were enrolled in this study. There 
were very few inclusion and exclusion criteria and it was 
designed as a real-life study. If the investigator believed, 
based on clinical data, that the BioPhotonic treatment would 
be an appropriate option, the patient might be included.
This interim analysis presents the data of the first 
33 subjects who completed the study, with the data being 
obtained from seven clinical sites. Patients were treated for a 
maximum period of 16 weeks (PU, VLU) to 24 weeks (DFU) 
or until wound closure. Once their wound closed, the patients 
were seen again three times over an 8-week period to confirm 
persistence of wound closure. Sixteen patients completed 
the last follow-up visit. The trial was conducted in compli-
ance with the Declaration of Helsinki and the Guidelines 
for Good Clinical Practice. Protocol and informed consent 
procedures were approved by the local ethics committees of 
the 12 sites involved in the study (complete list of local ethics 
committees in Table 1), and all patients signed an informed 
consent form. The sites were all centers specializing in the 
management of chronic wounds (VLUs, DFUs, PUs). All 
of them were monitored at regular intervals throughout the 
study period. This interim analysis includes only subjects 
who completed the study and for whom complete data were 
available for review.
patients
A total of 33 patients (mean age 67.60 years) with DFUs, 
PUs, and VLUs were enrolled and treated, at least once. 
PUs were categorized according to grades numbered from 
one to four of the European Pressure Ulcer Advisory Panel 
and National Pressure Ulcer Advisory Panel.18 The grading 
system used for DFUs was the University of Texas Wound 
Classification System.19 For VLUs, the criterion was the pres-
ence of a diagnosed VLU (open leg ulcer, with the presence 
of a venous disease).
Treatment
BioPhotonic gel is a photo-converter wound gel containing 
specific light-absorbing molecules (chromophores) which are 
Table 1 list of ethics committees
Comitato etico Sperimentazione Clinica CeaVno
Comitato etico regionale liguria – Sez. 2
Comitato etico per la Sperimentazione Clinica della provincia di padova
Comitato etico regionale liguria
Comitato etico interaziendale aoU San luigi Gonzaga di orbassano
Comitato etico regionale Unico – CerU
Comitato etico irST-irCCS aVr – CeiiaV
Comitato etico regionale delle Marche
Comitato etico interaziendale a.o.U Citta della Salute e della Scienza 
di Torino
Comitato etico per la Sperimentazione Clinica-CeSC-delle provincie 
di Verona e rovigo
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not absorbed by the skin. The chromophores are illuminated 
by a multi-LED lamp, which is a device delivering blue light 
with wavelengths between 440 and 460 nm and a power 
density of between 55 and 129 mW/cm2 at a distance of 5 cm 
from the light source.
Upon illumination by the blue light, the chromophores 
release an ultra-fast micropulsed emission of photons in 
the form of fluorescence, with different wavelengths in the 
spectra of visible light, ranging from 500 to 610 nm. The 
use of the BioPhotonic gel illuminated by a multi-LED lamp 
was proven to be non-irritating for the skin and safe to use 
on wounds according to in vitro studies, in vivo studies per-
formed in rabbits, rats and pigs, and previous clinical trials 
performed with the same gel on VLUs, DFUs, and PUs. The 
photo-converter wound gel is presented in two jars, which 
have to be mixed together just prior to application.
The bi-weekly BioPhotonic gel treatment regimen was 
used in combination with standard of care specific to each 
type of chronic wound (PUs, DFUs, VLUs). Typically, upon 
evaluation, any excess fibrin or necrotic tissue was debrided. 
The wound was cleansed with normal saline and a 2 mm thick 
layer of the gel was applied on the ulcers. The wound was 
then illuminated with the multi-LED light for 5 minutes at a 
distance of 5 cm. Once the treatment was completed, the gel 
was removed from the wound with gentle saline irrigation. 
A non-adherent dressing was then applied to prevent any 
contact between the wound and the external environment. 
Standard of care adapted to each ulcer was then followed, 
including: compression bandage systems, offloading, pres-
sure reduction, management of a moist wound environment, 
use of barrier creams, management of wound infection, and 
nutritional assessment.
Efficacy analysis
Efficacy was assessed through the following endpoints: rate 
of complete wound closure; time to complete wound clo-
sure; wound area reduction over time; incidence of wound 
breakdown, following closure; impact of treatment quality 
of life (QOL); and ease of use by health care professionals. 
Wound area evaluation (mean change in wound area over 
time) was performed via the Silhouette™ Imaging System 
(ARANZ Medical, Christchurch, New Zealand), a device 
linked to a computerized system, allowing wound pictures 
and assessments of key characteristics (area, volume, depth, 
etc), as previously reported by Romanelli et al.20 Moreover, 
the following criteria were developed by the sponsor and 
used to define the response to the treatment: 1) full responder: 
decrease of the wound size area of more than 90% at the end 
of the study period and/or decrease of more than 50% of 
the size in 15 days or less; 2) partial responder: decrease of 
the size of the wound during the study period, but without 
meeting the criteria of full responders; 3) non-responder: 
increase of the size of the wound during the study period. 
The same criteria were used for all the types of wounds (PUs, 
DFUs, VLUs).
Safety analysis
Safety was documented via the collection of the following 
parameters: adverse events; serious adverse events; device 
incidents; clinical laboratory parameters; vital signs; physical 
examinations; pain; proportion of subjects with wound clini-
cal infection requiring systemic antimicrobial therapy.
Qol measurements
The Cardiff Wound Impact Schedule (CWIS) is a wound-
specific tool designed for subjects affected by chronic 
ulcers. This questionnaire was chosen for its consistency, 
its ability to discriminate between health states, and its 
good reproducibility.21 It was used to assess the impact of 
treatment on the QOL of patients involved in the study. 
The CWIS includes a total score and three main domains 
(“sub-scores”): “social life”, “well-being”, and “physical 
symptoms and daily living”. The questionnaire is designed 
to be self-administered and it was administered at baseline 
as well as at the first follow-up visit.
pain assessment
Specific information on pain was collected by investigators. 
They were asked to assess the presence or absence of wound 
pain at each treatment visit. Intensity of this pain was not 
assessed.
ease of use/satisfaction
The ease of use of the lamp and the gel was assessed by the 
investigators at the first and last treatment visits, through 
specific questionnaires developed by the sponsor.
As 33 subjects completed the study and were included in 
this interim analysis, a total of 66 questionnaires (33 at visit 
1 or study start, and 33 at “end of study”) were collected.
For each question, investigators had to assess their sat-
isfaction by selecting one box on a seven-box scale ranging 
from “very satisfied” to “very unsatisfied”.
Statistical analysis
As it was a real-life reproducibility study, analyses were pri-
marily descriptive in nature in this interim analysis. There was 
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no formal sample size calculation. Sample size was based on 
clinical considerations and no statistical power calculations. 
A maximum number of 100 patients were to be enrolled in 
this study. There was no blinding in this study. Safety analysis 
was carried out on the intent-to-treat population, which was 
the same as the efficacy population; it consisted of all patients 
having received at least one treatment. CWIS scores were 
analyzed using paired Student’s t-tests, and a p-value ,0.05 
was considered as statistically significant.
Results
Among the 33 subjects, 17 had DFUs (five stage 1A and 12 
stage 2A), three had PUs (two stage II and 1 stage III), and 
13 had VLUs. The average duration of the chronic ulcers 
under study was 72.3 weeks at screening (52.0 weeks for 
PUs, 54.7 weeks for DFUs, and 98.6 weeks for VLUs). As 
it was a real-life study, the dimensions of the chronic ulcers 
treated in the study were different depending on the type of 
wound. The average area of PUs was 2.9 cm2 at screening 
(SD: 3.1 cm2), while the average area of DFUs and VLUs 
was 1.8 cm2 (SD: 2.02 cm2) and 13.2 cm2 (SD: 10.9 cm2), 
respectively.
Efficacy of study endpoints
Despite the heterogeneity of the different chronic wounds, 
the use of this novel technology demonstrated a significant 
efficacy profile. Table 2 shows the response of the 33 subjects 
included in this interim analysis. Twenty-one patients were 
considered as full responders (64%), six as partial responders 
(18%), and six as non-responders (18%). The wound size 
of full responders decreased on average by 78% at day 30 
(20 subjects), and by 99% at day 60 (17 subjects). By type 
of wound, these percentages were respectively: 78% and 
100% for PUs; 76% and 99% for DFUs; 81% and 97% for 
VLUs. As shown in Table 3, the percentage of full responders 
was higher for DFUs (12 out 17 subjects – 70%) and VLUs 
(eight out of 13 subjects – 62%). As only three patients were 
included in the PU group, results were not interpretable 
for this category.
Among the full responders, 17 subjects achieved complete 
ulcer closure (complete wound closure rate of 100.0%) with 
a mean time to closure of 39.8 days. In particular, nine were 
from the DFU group (mean time: 28.3 days), seven from the 
VLU group (mean time: 53.6 days), and one was from the 
PU group (47.0 days). Moreover, no case of wound break-
down was observed during the 2-week follow-up period after 
wound closure. Figures 1 and 2 show the mean wound area 
variation in the full responders of DFU and VLU groups, 
respectively. As shown in these figures, the mean time to 
reach a 50% decrease of the wound size area in full responders 
was 19 days for DFUs and 22 days for VLUs. Among the six 
partial responders, three were from the DFU group and three 
from the VLU group. Two of them became ready for skin 
grafting according to investigators. The size of these partially 
responding wounds decreased from 24% to 43% for DFUs, 
and from 38% to 60% for VLUs during the study period. 
There were six non-responders, two were from the PU group, 
two from the DFU group, and two from the VLU group.
Safety and tolerability
There was only one related adverse event of the study lead-
ing to a discontinuation of a subject. The patient reported 
intermittent erythema following the use of the BioPhotonic 
gel. However, this adverse event was considered of mild 
intensity by the investigator. No related serious adverse 
events were reported in any subject receiving the treatment. 
The safety profile reported in this interim analysis is similar 
to what has been observed in previous clinical trials using 
the BioPhotonic gel in subjects with chronic wounds.22,23 
Furthermore, the treatment did not cause any clinically 
significant abnormal values in laboratory analyses, either 
biochemical, hematological or in urine. There was no clini-
cally significant impact on vital signs, and no negative impact 
observed during the physical examinations. Compliance was 
also excellent with only two subjects missing more than two 
expected visits.
Table 2 incidence of wound closure
Number  
of wounds
Percentage of 
total wounds
Closed 17 51.5%
almost closed 2 6.1%
ready for skin grafting 3 9.1%
other 11 33.3%
Total 33 100.0%
Note: after the treatment, the wounds of 22 patients out of 33 (66.7%) closed, 
almost closed, or became ready for skin grafting.
Table 3 Full responders by type of wound
Number  
of wounds
Number of full  
responders
Percentage of  
full responders
VlU 13 8 61.5%
DFU 17 12 70.6%
pU 3 1 33.3%
Total 33 21 63.6%
Notes: The table shows the percentage of full responders after the treatment. The 
higher value of full responders was observed for DFU (12 out 17 subjects – 70.6%) 
and VlU (eight out of 13 subjects – 61.5%) groups.
Abbreviations: VlU, venous leg ulcer; DFU, diabetic foot ulcer; pU, pressure 
ulcer.
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Tolerability was also assessed through the assessment of 
pain. Presence of pain was assessed by investigators at every 
treatment visit through a questionnaire. After the treatment, 
wound pain disappeared in 100% of the patients who declared 
having pain at baseline. The VLU group is the population 
of subjects most concerned by pain among chronic ulcer 
patients. In this group, the pain was present at baseline in 
54% of the subjects. Pain systematically disappeared once 
the treatment with the BioPhotonic gel was initiated, with an 
average time to “no pain” of 11.9 days (meaning a maximum 
of four treatments with the BioPhotonic gel); the maximum 
time being 14 days (Table 4). Once disappeared, the wound 
pain never reappeared during the treatment period. Addition-
ally, although unrelated to the treatment, only one wound on 
Figure 1 Mean wound area reduction (in % vs the size at screening) in DFU full responders.
Note: The graph presents the wound area variations over time.
Abbreviation: DFU, diabetic foot ulcer.
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Figure 2 Mean wound area reduction (in % vs the size at screening) in VlU full responders.
Note: The graph presents the wound area variations over time.
Abbreviation: VlU, venous leg ulcer.
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a VLU patient developed an infection (erysipelas) during the 
study period. Except for this case, no other wound infection 
(related or unrelated to the study treatment) was observed. 
No wound presenting clinical signs of wound colonization 
was observed in the DFU and PU groups during the treatment 
period. These data, already observed in previous clinical 
studies with the same medical device,22,23 may support the 
hypothesis of control of wound colonization. Taken together, 
these results clearly demonstrate a favorable tolerability and 
safety profile.
Qol outcomes
The standardized questionnaire CWIS was used to evalu-
ate the impact of the treatment on the QOL of the patients. 
Despite a high score at screening, the overall QOL index 
was significantly improved during the study period, with an 
overall increase of 26.4% of the mean total score, from 196.6 
(SD: 56.4) at screening to 248.5 (SD: 54.2) at follow-up 
(p=0.001) (Figure 3). This positive increase was observed in 
both full and partial responders. It is reasonable to speculate 
that this improvement of QOL may be linked to the positive 
impact observed on pain reduction. There was an overall 
improvement in all domains of the CWIS. The greatest 
improvement was seen in the well-being component, for each 
type of wound, with a mean increase of 44.7% (p=0.002) 
(Figure 3). A significant improvement was also observed in 
the physical symptoms (+18.4%, p=0.019) and social life 
domains (+22.3%, p=0.001) (Figure 3). Therefore, these data 
indicate a high confidence of the subjects in the efficacy of 
the treatment throughout the study period.
ease of use/satisfaction
High levels of satisfaction have been reported by the health 
care providers throughout the study period, with 95% of the 
assessments reporting that investigators would recommend 
the BioPhotonic gel to their colleagues.
Discussion
This study was designed to address the safety and efficacy 
of the BioPhotonic gel for the treatment of chronic wounds 
such as DFUs, PUs, and VLUs. The clinical evaluation of 
the use of PBM through the BioPhotonic gel was positive. 
In this interim analysis, the use of the BioPhotonic gel was 
associated with an excellent safety profile. There were 
no treatment-related serious adverse events and only one 
patient reported a mild intermittent erythema following 
the treatment. Tolerability was also evaluated through the 
assessment of pain. Despite the fact that procedures for treat-
ment of chronic ulcers, particularly VLUs, may be generally 
considered as painful and/or uncomfortable,24,25 the results 
showed that, when the pain was initially present before the 
first treatment it disappeared once this first treatment was 
initiated. We observed an average pain-free time of 9.8 days 
(all wounds), meaning that on average a maximum of three 
treatments was needed to remove that pain. Compared to 
the existing treatment solutions for chronic ulcers, this is an 
additional advantage of the BioPhotonic gel.
Even if compliance to the study may be an issue with 
patients affected by chronic wounds, in this interim analy-
sis the treatment regimen led to a high rate of compliance. 
As reported by Lavery et al for DFUs,26 wound infections 
are frequent and responsible for delayed wound healing 
and wound breakdowns. We previously observed that the 
BioPhotonic gel treatment on chronic wounds decreased the 
susceptibility to wound infection.22 The overall incidence of 
infection in our study was lower than we estimated, reporting 
only one case of erysipelas unrelated to the treatment on a 
VLU patient. Although these results need to be further inves-
tigated, the absence of wound infections may be associated 
with the effects of the treatment to control bacteria involved 
in colonization in wound surfaces.
Efficacy profile may also be considered as very sat-
isfying, with 17 wounds (52% of total wounds) totally 
closed and 21 wounds (67%) considered as full responders. 
Figure 3 Mean score of the quality of life assessments from screening to the last 
follow-up visit – all wounds. *p=0.001.
Note: The quality of life was measured by using CWiS (Cardiff Wound impact 
Schedule) questionnaire and its domains.
????????????? ??????????????
?????
???????????????????? ???????????
?????
?????? ?
Table 4 impact on pain (VlU only)
number of subjects declaring pain at baseline 7
Minimum time to no-pain (days) 7
Maximum time to no-pain (days) 14
average time to no-pain (days) 11.86
Note: evolution of the pain in patients declaring pain at baseline, according to the 
investigators.
Abbreviation: VlU, venous leg ulcer.
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These efficacy results will however need to be confirmed by 
a randomized controlled trial. In addition, no case of wound 
breakdown was observed 2 weeks after wound closure in 
the PU, VLU, and DFU groups and we were also able to 
assess the perseverance of wound closure in the majority of 
the subjects during the 8-week follow-up period. The study 
has shown that the BioPhotonic gel enhances wound healing 
through promotion of the healing process of chronic, hard-to-
heal wounds, which were reactivated with an appropriate and 
efficient wound bed preparation. This efficacy was particu-
larly remarkable on VLUs and DFUs, especially considering 
the age of these wounds at screening and their hard-to-heal 
status.27–29 Even if excellent and superior to the majority of 
the results observed in the literature,30–34 the results in DFUs 
will however need to be confirmed as the majority of these 
DFU wounds were of small size and of stages 1a and 2a.
Hard-to-heal wounds have a negative impact on patient 
well-being. For this reason, we investigated the impact of 
the treatment on the QOL of the subjects. The total score 
of CWIS increased during the study period for all wounds 
(+26.4%), confirming the positive impact of the treatment 
on overall aspects of QOL for subjects with chronic wounds. 
This positive tendency was also observed with the three 
sub-scores: social life (+22.3%), well-being (+44.7%), and 
physical symptoms/daily living (+18.4%) (Figure 3).
A critical success factor of the efficacy of this treatment 
was the clinical usability of the BioPhotonic gel. The high 
levels of satisfaction reported in the study support the positive 
experience of using the BioPhotonic gel in the treatment of 
complex chronic wounds.
There are some limitations in this study that should be 
noted. Since the purpose of this study was to assess the 
efficacy of the BioPhotonic gel in a real-life setting in dif-
ferent investigating centers, there was no formal sample size 
calculation for each group, and no control group. There was 
also a limited number of inclusion and exclusion criteria in 
this multi-center study. This resulted in a diversity of wound 
characteristics, especially in terms of wound size and previ-
ous standard of care. Another limitation is the fact that the 
multi-LED lamp needs to be used in a clinical setting.
Conclusion
The device used in this study offers an important and promis-
ing new therapeutic option in the treatment of hard-to-heal 
chronic wounds. Effective features of the system in this non-
controlled trial include the efficacy profile associated with 
promotion of wound healing in different types of chronic 
wounds, safety and tolerability, improvement of the QOL, 
and positive impact on pain reduction. These preliminary data 
suggest that the studied BioPhotonic gel has the potential to 
become an alternative for unmet needs in the management 
of chronic ulcers.
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